UBS initiated coverage on Acumen Pharmaceuticals with a new price target

7/26/21 8:57:51 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

UBS initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $27.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ABOS

Date	Price Target	Rating	Analyst
6/17/2025	$4.00	Buy	Citigroup
7/26/2024	$7.00	Buy	Citigroup
12/12/2023	$8.00	Buy	Deutsche Bank
7/20/2023	$9.00 → $14.00	Buy	BofA Securities
5/18/2023	$13.00	Overweight	Cantor Fitzgerald
7/15/2022	$15.00	Buy	BTIG Research
6/30/2022	$15.00	Buy	H.C. Wainwright
1/21/2022	$16.00 → $14.00	Neutral → Buy	B of A Securities